These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8179721)

  • 1. Problems associated with susceptibility testing of co-amoxiclav: an interpretive solution.
    Alós JI
    J Antimicrob Chemother; 1994 Jan; 33(1):183. PubMed ID: 8179721
    [No Abstract]   [Full Text] [Related]  

  • 2. Problems associated with susceptibility testing of co-amoxiclav.
    Ellis R; Andrews J; Wise R
    J Antimicrob Chemother; 1993 Mar; 31(3):443-5. PubMed ID: 8486581
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei.
    Dance DA; Wuthiekanun V; Chaowagul W; Suputtamongkol Y; White NJ
    J Antimicrob Chemother; 1991 Aug; 28(2):321-4. PubMed ID: 1723404
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of NCCLS, SFM, and DIN breakpoints upon the incidence of co-amoxiclav resistance in Escherichia coli.
    Durodia J; Simpson I
    J Antimicrob Chemother; 1995 Dec; 36(6):1105-6. PubMed ID: 8821615
    [No Abstract]   [Full Text] [Related]  

  • 5. The antibacterial activity of co-amoxiclav.
    Barry AL; Pfaller MA; Fuchs PC
    J Antimicrob Chemother; 1993 Apr; 31(4):612-5. PubMed ID: 8514658
    [No Abstract]   [Full Text] [Related]  

  • 6. [The development of bacterial resistance and the role of clavulanic acid].
    Rolinson JN
    Antibiot Khimioter; 1992 Sep; 37(9):11-4. PubMed ID: 1444658
    [No Abstract]   [Full Text] [Related]  

  • 7. [The antimicrobial activity of Augmentin (amoxicillin/clavulanic acid) compared to other antibacterial agents].
    Zubkov MN; Nonikov VE; Gugutsidze EN; Sutormina TM; Makarova OV
    Antibiot Khimioter; 1992 Sep; 37(9):34-6. PubMed ID: 1444669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro efficacy of augmentin in beta-lactamase producing bacteria.
    Agrawal SK; Goel MM; Misra AB
    Indian J Med Res; 1987 Sep; 86():298-300. PubMed ID: 3501408
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitivity of clinical isolates from German hospitals to amoxicillin/clavulanic acid (Augmentin) compared with other antibiotics.
    Focht J; Klietmann W; Nösner K; Rolinson GN; Johnsen J
    Chemotherapy; 1988; 34(4):332-40. PubMed ID: 3264780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group.
    Chardon H; Farzaneh S; Labia R; Jarlier V; Nicolas MH; Paul G; Poyart C; Sirot D; Sirot J
    J Antimicrob Chemother; 1995 Jul; 36(1):267-9. PubMed ID: 8537279
    [No Abstract]   [Full Text] [Related]  

  • 11. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
    Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI
    J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to amoxicillin/clavulanate in Escherichia coli.
    Colaert J
    Acta Clin Belg; 1992; 47(5):353-4. PubMed ID: 1334324
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of sensitivity of Mycobacterium spp. to combinations of clavulanic acid & penicillins with certain antitubercular agents.
    Bhattacharya CP; Charkrabarty AN; Dastidar SG
    Indian J Med Res; 1988 Aug; 88():118-23. PubMed ID: 3198169
    [No Abstract]   [Full Text] [Related]  

  • 14. Beta-lactamase inhibitors and Acinetobacter spp.
    Eng RH; Smith SM; Cherubin CE
    J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200
    [No Abstract]   [Full Text] [Related]  

  • 15. Exacerbation of COPD: amoxicillin + clavulanic acid in vitro activity vs S. pneumoniae, H. influenzae and M. catarrhalis.
    Beghi G; Legnani D; De Bartolo A; Pagani N; Lusco G
    J Chemother; 1995 Nov; 7 Suppl 4():61-2. PubMed ID: 8904109
    [No Abstract]   [Full Text] [Related]  

  • 16. Resistance to amoxicillin/clavulanate in Escherichia coli.
    Glupczynski Y; Mac Gillavry G; Yourassowsky E
    Acta Clin Belg; 1992; 47(5):354-5. PubMed ID: 1334325
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined therapy with co-amoxiclav and erythromycin against intracellular Legionella pneumophila in cell culture and in an experimental respiratory infection in neutropenic rats.
    Smith GM; Abbott KH; Beale AS
    J Antimicrob Chemother; 1995 Jun; 35(6):889-93. PubMed ID: 7559201
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced susceptibility to co-amoxiclav in Escherichia coli, Salmonella typhimurium and Klebsiella pneumoniae isolated in Romania between 1985 and 1993.
    Espinasse F; Gheorghiu R; Poiata A; Labia R; Nicolas-Chanoine MH
    J Antimicrob Chemother; 1997 Jan; 39(1):103-6. PubMed ID: 9044036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of bacterial respiratory pathogens to amoxicillin and amoxicillin-clavulanic acid.
    Barry AL; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1994 May; 13(5):442-4. PubMed ID: 8070465
    [No Abstract]   [Full Text] [Related]  

  • 20. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J; Hupková M; Krcméry V
    Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.